Drug Approval | December 04, 2025
FDA nod to priority review to AstraZeneca’s Baxdrostat for hard-to-control hypertension
Here's a development that aims to keep your blood pressure in check. Literally!
Here's a development that aims to keep your blood pressure in check. Literally!
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The medicine was well tolerated, with no unexpected safety issue
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
CSPC will receive an upfront payment of $100 million from AstraZeneca
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Subscribe To Our Newsletter & Stay Updated
